Molecular imaging of breast cancer: Present and future directions

Frontiers in Chemistry

Volumn 2, Issue , 2014, Pages

  Alcantara, David ^a   Leal, Manuel Pernia ^a   García Bocanegra, Irene ^a   García Martín, Maria L ^a  

^a Institute of Biomedical Research in Malaga and BIONAND Nanomedicine Platform   (Spain)

Author keywords

Breast cancer; Breast cancer diagnosis; Breast imaging techniques; Breast magnetic resonance imaging; Contrast agents; Molecular imaging of breast

Indexed keywords

EID: 84980009730     PISSN: None     EISSN: 22962646     Source Type: Journal    
DOI: 10.3389/fchem.2014.00112     Document Type: Review

References (98)

1. Adamczyk, B., Tharmalingam, T., and Rudd, P. M. (2012). Glycans as cancer biomarkers. Biochim. Biophys. Acta 1820, 1347-1353. doi: 10.1016/j.bbagen.2011.12.001
2. Agner, S. C., Rosen, M. a., englander, s., tomaszewski, j. e., feldman, m. d., zhang, p., et al. (2014). computerized image analysis for identifying triple-negative breast cancers and differentiating them from other molecular subtypes of breast cancer on dynamic contrast-enhanced MR images: a feasibility study. Radiology 272, 91-99. doi: 10.1148/radiol.14121031
3. Agrawal, G., Su, M. Y., Nalcioglu, O., Feig, S. A., and Chen, J. H. (2009). Significance of breast lesion descriptors in the ACR BI-RADS MRI lexicon. Cancer 115, 1363-1380. doi: 10.1002/cncr.24156
4. Alakhras, M., Bourne, R., Rickard, M., Ng, K. H., Pietrzyk, M., and Brennan, P. C. (2013). Digital tomosynthesis: a new future for breast imaging? Clin. Radiol. 68, e225-236. doi: 10.1016/j.crad.2013.01.007
5. Alcantara, D., Blois, J., and Ceacero, C. (2010). Editorial. All Results J. Biol. 1, 1-3.
6. American College of Radiology. (2003). Breast Imaging Reporting and Data System Atlas. Reston, VA: BI-RADS Atlas.
7. Anderson, G., Sprott, H., and Olsen, B. R. (2013). Opinion: publish negative results. Scientist. Available online at: http://www.the-scientist.com/?articles.view/articleNo/33968/title/Opinion-Publish-Negative-Results/
8. Barrett, B. J., Parfrey, P. S., McDonald, J. R., Hefferton, D. M., Reddy, E. R., and McManamon, P. J. (1992). Nonionic low-osmolality versus ionic high-osmolality contrast material for intravenous use in patients perceived to be at high risk: randomized trial. Radiology 183, 105-110. doi: 10.1148/radiology.183.1.1549654
9. Begley, J. K., Redpath, T. W., Bolan, P. J., and Gilbert, F. J. (2012). In vivo proton magnetic resonance spectroscopy of breast cancer: a review of the literature. Breast Cancer Res. 14, 207. doi: 10.1186/bcr3132
10. Bolan, P. J. (2013). Magnetic resonance spectroscopy of the breast: current status. Magn. Reson. Imaging Clin. N. Am. 21, 625-639. doi: 10.1016/j.mric.2013.04.008
11. Brozek-Pluska, B., Musial, J., Kordek, R., Bailo, E., Dieing, T., and Abramczyk, H. (2012). Raman spectroscopy and imaging: applications in human breast cancer diagnosis. Analyst 137, 3773-3780. doi: 10.1039/c2an16179f
12. Burnside, E. S., Sickles, E. A., Bassett, L. W., Rubin, D. L., Lee, C. H., Ikeda, D. M., et al. (2009). The ACR BI-RADS® experience: learning from history. J. Am. Coll. Radiol. 6, 851-860. doi: 10.1016/j.jacr.2009.07.023
13. Caldarella, C., Treglia, G., and Giordano, A. (2014). Diagnostic performance of dedicated positron emission mammography using fluorine-18-fluorodeoxyglucose in women with suspicious breast lesions: a meta-analysis. Clin. Breast Cancer 14, 241-248. doi: 10.1016/j.clbc.2013.12.004
14. Cheng, Z., Thorek, D. L., and Tsourkas, A. (2010). Gadolinium-conjugated dendrimer nanoclusters as a tumor-targeted T1 magnetic resonance imaging contrast agent. Angew. Chem. Int. Ed. Engl. 49, 346-350. doi: 10.1002/anie.200905133
15. Cho, H., Alcantara, D., Yuan, H., Sheth, R. A., Chen, H. H., Huang, P., et al. (2013). Fluorochrome-functionalized nanoparticles for imaging DNA in biological systems. ACS Nano 7, 2032-2041. doi: 10.1021/nn305962n
16. Coffey, J. P., and Hill, J. C. (2010). Breast sentinel node imaging with low-dose SPECT/CT. Nucl. Med. Commun. 31, 107-111. doi: 10.1097/MNM.0b013e32832ed3a6
17. Contractor, K. B., Kenny, L. M., Stebbing, J., Al-Nahhas, A., Palmieri, C., Sinnett, D., et al. (2009). [11C]choline positron emission tomography in estrogen receptor-positive breast cancer. Clin. Cancer Res. 15, 5503-5510. doi: 10.1158/1078-0432.CCR-09-0666
18. De Mattos-Arruda, L., Cortes, J., Santarpia, L., Vivancos, A., Tabernero, J., Reis-Filho, J. S., et al. (2013). Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat. Rev. Clin. Oncol. 10, 377-389. doi: 10.1038/nrclinonc.2013.80
19. D'orsi, C. J., and Kopans, D. B. (1997). Mammography interpretation: the BI-RADS method. Am. Fam. Physician 55, 1548-1550, 1552.
20. Dromain, C., Balleyguier, C., Adler, G., Garbay, J. R., and Delaloge, S. (2009). Contrast-enhanced digital mammography. Eur. J. Radiol. 69, 34-42. doi: 10.1016/j.ejrad.2008.07.035
21. Eccles, S. A., Aboagye, E. O., Ali, S., Anderson, A. S., Armes, J., Berditchevski, F., et al. (2013). Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res. 15, R92. doi: 10.1186/bcr3493
22. Ellenbroek, S. I. J., and Van Rheenen, J. (2014). Imaging hallmarks of cancer in living mice. Nat. Rev. Cancer 14, 406-418. doi: 10.1038/nrc3742
23. Esposito, A., Bardelli, A., Criscitiello, C., Colombo, N., Gelao, L., Fumagalli, L., et al. (2014). Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. Cancer Treat. Rev. 40, 648-655. doi: 10.1016/j.ctrv.2013.10.003
24. Fallenberg, E. M., Dromain, C., Diekmann, F., Renz, D. M., Amer, H., Ingold-Heppner, B., et al. (2014). Contrast-enhanced spectral mammography: does mammography provide additional clinical benefits or can some radiation exposure be avoided? Breast Cancer Res. Treat. 146, 371-381. doi: 10.1007/s10549-014-3023-6
25. Fleischhacker, M., and Schmidt, B. (2007). Circulating nucleic acids (CNAs) and cancer-a survey. Biochim. Biophys. Acta 1775, 181-232. doi: 10.1016/j.bbcan.2006.10.001
26. Fornvik, D., Zackrisson, S., Ljungberg, O., Svahn, T., Timberg, P., Tingberg, A., et al. (2010). Breast tomosynthesis: accuracy of tumor measurement compared with digital mammography and ultrasonography. Acta Radiol. 51, 240-247. doi: 10.3109/02841850903524447
27. Gambini, J. P., Cabral, P., Alonso, O., Savio, E., Figueroa, S. D., Zhang, X., et al. (2011). Evaluation of 99mTc-glucarate as a breast cancer imaging agent in a xenograft animal model. Nucl. Med. Biol. 38, 255-260. doi: 10.1016/j.nucmedbio.2010.08.002
28. Greaves, M., and Maley, C. C. (2012). Clonal evolution in cancer. Nature 481, 306-313. doi: 10.1038/nature10762
29. Guo, Y., Cai, Y. Q., Cai, Z. L., Gao, Y. G., An, N. Y., Ma, L., et al. (2002). Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J. Magn. Reson. Imaging 16, 172-178. doi: 10.1002/jmri.10140
30. Harbeck, N., Schmitt, M., Meisner, C., Friedel, C., Untch, M., Schmidt, M., et al. (2013). Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur. J. Cancer 49, 1825-1835. doi: 10.1016/j.ejca.2013.01.007
31. Houssami, N., Given-Wilson, R., and Ciatto, S. (2009). Early detection of breast cancer: overview of the evidence on computer-aided detection in mammography screening. J. Med. Imaging Radiat. Oncol. 53, 171-176. doi: 10.1111/j.1754-9485.2009.02062.x
32. Huang, C. H., and Tsourkas, A. (2013). Gd-based macromolecules and nanoparticles as magnetic resonance contrast agents for molecular imaging. Curr. Top. Med. Chem. doi: 10.2174/1568026611313040002
33. Husarik, D. B., and Steinert, H. C. (2007). Single-photon emission computed tomography/computed tomographyfor sentinel node mapping in breast cancer. Semin. Nucl. Med. 37, 29-33. doi: 10.1053/j.semnuclmed.2006.08.001
34. Itoh, A., Ueno, E., Tohno, E., Kamma, H., Takahashi, H., Shiina, T., et al. (2006). Breast disease: clinical application of US elastography for diagnosis. Radiology 239, 341-350. doi: 10.1148/radiol.2391041676
35. Ittrich, H., Peldschus, K., Raabe, N., Kaul, M., and Adam, G. (2013). Superparamagnetic iron oxide nanoparticles in biomedicine: applications and developments in diagnostics and therapy. Rofo 185, 1149-1166. doi: 10.1055/s-0033-1335438
36. Jia, W. R., Chai, W. M., Tang, L., Wang, Y., Fei, X. C., Han, B. S., et al. (2014). Three-dimensional contrast enhanced ultrasound score and dynamic contrast-enhanced magnetic resonance imaging score in evaluating breast tumor angiogenesis: correlation with biological factors. Eur. J. Radiol. 83, 1098-1105. doi: 10.1016/j.ejrad.2014.03.027
37. Jin, R., Lin, B., Li, D., and Ai, H. (2014). Superparamagnetic iron oxide nanoparticles for MR imaging and therapy: design considerations and clinical applications. Curr. Opin. Pharmacol. 18C, 18-27. doi: 10.1016/j.coph.2014.08.002
38. Kallaway, C., Almond, L. M., Barr, H., Wood, J., Hutchings, J., Kendall, C., et al. (2013). Advances in the clinical application of Raman spectroscopy for cancer diagnostics. Photodiagnosis Photodyn. Ther. 10, 207-219. doi: 10.1016/j.pdpdt.2013.01.008
39. Kalles, V., Zografos, G. C., Provatopoulou, X., Koulocheri, D., and Gounaris, A. (2013). The current status of positron emission mammography in breast cancer diagnosis. Breast Cancer 20, 123-130. doi: 10.1007/s12282-012-0433-3
40. Kievit, F. M., and Zhang, M. (2011). Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Acc. Chem. Res. 44, 853-862. doi: 10.1021/ar2000277
41. Kjaer, A. (2006). Molecular imaging of cancer using PET and SPECT. Adv. Exp. Med. Biol. 587, 277-284. doi: 10.1007/978-1-4020-5133-3_21
42. Klintman, M., Nilsson, F., Bendahl, P.-O., Fernö, M., Liljegren, G., Emdin, S., et al. (2013). A prospective, multicenter validation study of a prognostic index composed of S-phase fraction, progesterone receptor status, and tumour size predicts survival in node-negative breast cancer patients: NNBC, the node-negative breast cancer trial. Ann. Oncol. doi: 10.1093/annonc/mdt186
43. Klomp, D. W., Van De Bank, B. L., Raaijmakers, A., Korteweg, M. A., Possanzini, C., Boer, V. O., et al. (2011). 31P MRSI and 1H MRS at 7 T: initial results in human breast cancer. NMR Biomed. 24, 1337-1342. doi: 10.1002/nbm.1696
44. Knowles, S. M., and Wu, A. M. (2012). Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J. Clin. Oncol. 30, 3884-3892. doi: 10.1200/JCO.2012.42.4887
45. Kondo, T. (2014). Inconvenient truth: cancer biomarker development by using proteomics. Biochim. Biophys. Acta 1844, 861-865. doi: 10.1016/j.bbapap.2013.07.009
46. Koolen, B. B., Vogel, W. V., Vrancken Peeters, M. J., Loo, C. E., Rutgers, E. J., and Valdes Olmos, R. A. (2012). Molecular imaging in breast cancer: from whole-body PET/CT to dedicated breast PET. J. Oncol. 2012, 438647. doi: 10.1155/2012/438647
47. Kuhl, C. (2007). The current status of breast MR imaging. Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. Radiology 244, 356-378. doi: 10.1148/radiol.2442051620
48. Lambin, P., Rios-Velazquez, E., Leijenaar, R., Carvalho, S., Van Stiphout, R. G., Granton, P., et al. (2012). Radiomics: extracting more information from medical images using advanced feature analysis. Eur. J. Cancer 48, 441-446. doi: 10.1016/j.ejca.2011.11.036
49. Lee, B. T., Hutteman, M., Gioux, S., Stockdale, A., Lin, S. J., Ngo, L. H., et al. (2010). The FLARE intraoperative near-infrared fluorescence imaging system: a first-in-human clinical trial in perforator flap breast reconstruction. Plast. Reconstr. Surg. 126, 1472-1481. doi: 10.1097/PRS.0b013e3181f059c7
50. Lerman, H., Lievshitz, G., Zak, O., Metser, U., Schneebaum, S., and Even-Sapir, E. (2007). Improved sentinel node identification by SPECT/CT in overweight patients with breast cancer. J. Nucl. Med. 48, 201-206. Availabe online at: http://jnm.snmjournals.org/content/48/2/201
51. Levi, J., Cheng, Z., Gheysens, O., Patel, M., Chan, C. T., Wang, Y., et al. (2007). Fluorescent fructose derivatives for imaging breast cancer cells. Bioconjug. Chem. 18, 628-634. doi: 10.1021/bc060184s
52. Li, K., Wen, S., Larson, A. C., Shen, M., Zhang, Z., Chen, Q., et al. (2013). Multifunctional dendrimer-based nanoparticles for in vivo MR/CT dual-modal molecular imaging of breast cancer. Int. J. Nanomedicine 8, 2589-2600. doi: 10.2147/IJN.S46177
53. Li, Q., Gao, Q., and Zhang, G. (2014). Classification for breast cancer diagnosis with Raman spectroscopy. Biomed. Opt. Express 5, 2435-2445. doi: 10.1364/BOE.5.002435
54. Liu, T., Zhang, J., Wang, X., Yang, J., Tang, Z., and Lu, J. (2014). Radiolabeled glucose derivatives for tumor imaging using SPECT and PET. Curr. Med. Chem. 21, 24-34. doi: 10.2174/09298673113209990254
55. Lobbes, M. B. I., Prevos, R., Smidt, M., Tjan-Heijnen, V. C. G., Van Goethem, M., Schipper, R., et al. (2013). The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review. Insights Imaging 4, 163-175. doi: 10.1007/s13244-013-0219-y
56. Lodhia, J., Mandarano, G., Ferris, N., Eu, P., and Cowell, S. (2010). Development and use of iron oxide nanoparticles (Part 1): synthesis of iron oxide nanoparticles for MRI. Biomed. Imaging Interv. J. 6:e12. doi: 10.2349/biij.6.2.e12
57. Mann, R. M., Kuhl, C. K., Kinkel, K., and Boetes, C. (2008). Breast MRI: guidelines from the European Society of Breast Imaging. Eur. Radiol. 18, 1307-1318. doi: 10.1007/s00330-008-0863-7
58. McLelland, R., Hendrick, R. E., Zinninger, M. D., and Wilcox, P. A. (1991). The American College of Radiology Mammography Accreditation Program. AJR Am. J. Roentgenol. 157, 473-479. doi: 10.2214/ajr.157.3.1872231
59. Meier, R., Henning, T. D., Boddington, S., Tavri, S., Arora, S., Piontek, G., et al. (2010). Breast cancers: MR imaging of folate-receptor expression with the folate-specific nanoparticle P1133. Radiology 255, 527-535. doi: 10.1148/radiol.10090050
60. Mercado, C. L. (2014). BI-RADS update. Radiol. Clin. North Am. 52, 481-487. doi: 10.1016/j.rcl.2014.02.008
61. Mirna Therapeutics, I. (2014). A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection, ed C.P.R.I.O. Available online at: ClinicalTrials.gov
62. Morris, E. A., Comstock, C. E., Lee, C. H., et al. (2013) "ACR BI-RADS® magnetic resonance imaging," in ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System (Reston, VA: American College of Radiology).
63. Mouliere, F., El Messaoudi, S., Pang, D., Dritschilo, A., and Thierry, A. R. (2014). Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. Mol. Oncol. 8, 927-941. doi: 10.1016/j.molonc.2014.02.005
64. Mulrane, L., Klinger, R., McGee, S. F., Gallagher, W. M., and O'connor, D. P. (2014). microRNAs: a new class of breast cancer biomarkers. Expert Rev. Mol. Diagn. 14, 347-363. doi: 10.1586/14737159.2014.901153
65. Ng, E. K. O., Li, R., Shin, V. Y., Jin, H. C., Leung, C. P. H., Ma, E. S. K., et al. (2013). Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS ONE 8:e53141. doi: 10.1371/journal.pone.0053141
66. Oliveira, S., Van Dongen, G. A., Stigter-Van Walsum, M., Roovers, R. C., Stam, J. C., Mali, W., et al. (2012). Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Mol. Imaging 11, 33-46.
67. Pace, L., Nicolai, E., Luongo, A., Aiello, M., Catalano, O. A., Soricelli, A., et al. (2014). Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues. Eur. J. Radiol. 83, 289-296. doi: 10.1016/j.ejrad.2013.11.002
68. Partridge, S. C. (2008). Future applications and innovations of clinical breast magnetic resonance imaging. Top. Magn. Reson. Imaging 19, 171-176. doi: 10.1097/RMR.0b013e31818a4090
69. Partridge, S. C., and McDonald, E. S. (2013). Diffusion Weighted Magnetic Resonance Imaging of the Breast: Protocol Optimization, Interpretation, and Clinical Applications. Magn. Reson. Imaging Clin. N. Am. 21, 601-624. doi: 10.1016/j.mric.2013.04.007
70. Penuelas, I., Dominguez-Prado, I., Garcia-Velloso, M. J., Marti-Climent, J. M., Rodriguez-Fraile, M., Caicedo, C., et al. (2012). PET tracers for clinical imaging of breast cancer. J. Oncol. 2012, 710561. doi: 10.1155/2012/710561
71. Peters, N. H., Borel Rinkes, I. H., Zuithoff, N. P., Mali, W. P., Moons, K. G., and Peeters, P. H. (2008). Meta-analysis of MR imaging in the diagnosis of breast lesions. Radiology 246, 116-124. doi: 10.1148/radiol.2461061298
72. Poellinger, A. (2012). Near-infrared imaging of breast cancer using optical contrast agents. J. Biophotonics 5, 815-826. doi: 10.1002/jbio.201200123
73. Polyak, K. (2014). Tumor heterogeneity confounds and illuminates: a case for Darwinian tumor evolution. Nat. Med. 20, 344-346. doi: 10.1038/nm.3518
74. Rhee, C. M., Bhan, I., Alexander, E. K., and Brunelli, S. M. (2012). Association between iodinated contrast media exposure and incident hyperthyroidism and hypothyroidism. Arch. Intern. Med. 172, 153-159. doi: 10.1001/archinternmed.2011.677
75. Robbins, J. B. P., Pozniak, M. A., (2010). Contrast Media Tutorial. Reston, VA: American College of Radiology. Available online at: https://www.radiology.wisc.edu/fileShelf/contrastCorner/files/ContrastAgentsTutorial.pdf
76. Rosen, J. E., Chan, L., Shieh, D.-B., and Gu, F. X. (2012). Iron oxide nanoparticles for targeted cancer imaging and diagnostics. Nanomed. Nanotechnol. Biol. Med. 8, 275-290. doi: 10.1016/j.nano.2011.08.017
77. Sano, K., Mitsunaga, M., Nakajima, T., Choyke, P. L., and Kobayashi, H. (2012). In vivo breast cancer characterization imaging using two monoclonal antibodies activatably labeled with near infrared fluorophores. Breast Cancer Res. 14, R61. doi: 10.1186/bcr3167
78. Sardanelli, F., Boetes, C., Borisch, B., Decker, T., Federico, M., Gilbert, F. J., et al. (2010). Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur. J. Cancer 46, 1296-1316. doi: 10.1016/j.ejca.2010.02.015
79. Scaperrotta, G., Ferranti, C., Costa, C., Mariani, L., Marchesini, M., Suman, L., et al. (2008). Role of sonoelastography in non-palpable breast lesions. Eur. Radiol. 18, 2381-2389. doi: 10.1007/s00330-008-1032-8
80. Segal, E., Sirlin, C. B., Ooi, C., Adler, A. S., Gollub, J., Chen, X., et al. (2007). Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat. Biotechnol. 25, 675-680. doi: 10.1038/nbt1306
81. Seoane, J., and De Mattos-Arruda, L. (2014). The challenge of intratumour heterogeneity in precision medicine. J. Intern. Med. 276, 41-51. doi: 10.1111/joim.12240
82. Si, H., Sun, X., Chen, Y., Cao, Y., Chen, S., Wang, H., et al. (2013). Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J. Cancer Res. Clin. Oncol. 139, 223-229. doi: 10.1007/s00432-012-1315-y
83. Sun, Y., Kim H. S., Park, J., Li, M., Tian, L., Choi, Y., et al. (2014). MRI of breast tumor initiating cells using the extra domain-B of fibronectin targeting nanoparticles Theranostics 4, 845-857. doi: 10.7150/thno.8343
84. Swaby, R., Sharma, C. N., and Jordan, V. C. (2007). SERMs for the treatment and prevention of breast cancer. Rev. Endocr. Metab. Disord. 8, 229-239. doi: 10.1007/s11154-007-9034-4
85. Thakor, A. S., and Gambhir, S. S. (2013). Nanooncology: the future of cancer diagnosis and therapy. CA Cancer J. Clin. 63, 395-418. doi: 10.3322/caac.21199
86. Tozaki, M., Sakamoto, M., Oyama, Y., Maruyama, K., and Fukuma, E. (2010). Predicting pathological response to neoadjuvant chemotherapy in breast cancer with quantitative 1H MR spectroscopy using the external standard method. J. Magn. Reson. Imaging 31, 895-902. doi: 10.1002/jmri.22118
87. Tsougos, I., Svolos, P., Kousi, E., Athanassiou, E., Theodorou, K., Arvanitis, D., et al. (2014). The contribution of diffusion tensor imaging and magnetic resonance spectroscopy for the differentiation of breast lesions at 3T. Acta Radiol. 55, 14-23. doi: 10.1177/0284185113492152
88. Utting, M., Werner, W., Dahse, R., Schubert, J., and Junker, K. (2002). Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer. Clin. Cancer Res. 8, 35-40. Available online at: http://clincancerres.aacrjournals.org/content/8/1/35.full
89. Van Der Ploeg, I. M., Olmos, R. A., Kroon, B. B., Rutgers, E. J., and Nieweg, O. E. (2009). The hidden sentinel node and SPECT/CT in breast cancer patients. Eur. J. Nucl. Med. Mol. Imaging 36, 6-11. doi: 10.1007/s00259-008-0910-2
90. Van De Ven, S. M., Elias, S. G., Chan, C. T., Miao, Z., Cheng, Z., De, A., et al. (2012). Optical imaging with her2-targeted affibody molecules can monitor hsp90 treatment response in a breast cancer xenograft mouse model. Clin. Cancer Res. 18, 1073-1081. doi: 10.1158/1078-0432.CCR-10-3213
91. Verbeek, F. P., Troyan, S. L., Mieog, J. S., Liefers, G. J., Moffitt, L. A., Rosenberg, M., et al. (2014). Near-infrared fluorescence sentinel lymph node mapping in breast cancer: a multicenter experience. Breast Cancer Res. Treat. 143, 333-342. doi: 10.1007/s10549-013-2802-9
92. Von Karsa, L., and Arrossi, S. (2013). Development and implementation of guidelines for quality assurance in breast cancer screening: the European experience. Salud Publica Mex. 55, 318-328. Available online at: http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0036-36342013000400010&lng=en
93. Waldherr, C., Cerny, P., Altermatt, H. J., Berclaz, G., Ciriolo, M., Buser, K., et al. (2013). Value of one-view breast tomosynthesis versus two-view mammography in diagnostic workup of women with clinical signs and symptoms and in women recalled from screening. AJR Am. J. Roentgenol. 200, 226-231. doi: 10.2214/AJR.11.8202
94. Waterton, J. C., and Pylkkanen, L. (2012). Qualification of imaging biomarkers for oncology drug development. Eur. J. Cancer 48, 409-415. doi: 10.1016/j.ejca.2011.11.037
95. Weissleder, R. (2006). Molecular imaging in cancer. Science 312, 1168-1171. doi: 10.1126/science.1125949
96. Yamaguchi, K., Abe, H., Newstead, G., Egashira, R., Nakazono, T., Imaizumi, T., et al. (2014). Intratumoral heterogeneity of the distribution of kinetic parameters in breast cancer: comparison based on the molecular subtypes of invasive breast cancer. Breast Cancer 1-7. doi: 10.1007/s12282-013-0512-0. [Epub ahead of print].
97. Yan, C., Wu, Y., Feng, J., Chen, W., Liu, X., Hao, P., et al. (2013). Anti-alphavbeta3 antibody guided three-step pretargeting approach using magnetoliposomes for molecular magnetic resonance imaging of breast cancer angiogenesis. Int. J. Nanomedicine 8, 245-255. doi: 10.2147/IJN.S38678
98. Zhou, Z., and Lu, Z. R. (2013). Gadolinium-based contrast agents for magnetic resonance cancer imaging. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 5, 1-18. doi: 10.1002/wnan.1198